Context Therapeutics announced that two patients have achieved a confirmed partial response, PR, among the first 12 patients enrolled in the Phase 2 OATH clinical trial evaluating the potential of Context’s oral progesterone receptor antagonist onapristone extended release, ONA-XR, in combination with anastrozole, ANA, to treat hormone receptor positive metastatic endometrial cancer. "Data from the ongoing Phase 2 OATH clinical trial supports the potential for ONA-XR plus ANA combination therapy to serve as an effective therapeutic option in metastatic EC. We are encouraged by these findings and look forward to continued enrollment in the trial," said Martin Lehr, CEO of Context Therapeutics. Preliminary data from the ongoing Phase 2 OATH clinical trial evaluating the combination of ONA-XR with ANA in HR+ EC found that ONA-XR plus ANA demonstrated a 4-month progression free survival rate of 77% and an overall response rate of 22%. These results suggest that ONA-XR plus ANA exhibits favorable efficacy and tolerability relative to historical data that evaluated physician’s choice of chemotherapy versus Lenvima plus Keytruda combination therapy in a similar treatment setting of metastatic EC.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CNTX:
- Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
- Context Therapeutics Stock Soars on FDA Approval
- Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
- Context announces Stemline received approval from U.S. FDA for ORSERDU
- Context Therapeutics, Lonza enter manufacturing agreement
